Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.

Cell reports. Medicine - 21 Jul 2026

Yan Huan, Jiang Wenjuan, Xiong Yi, Liu Li, Zhang Renzhi, Ruan Zhaohui, Huang Zhe, Dai Jiacheng, Tian Fang, Zhou Chunhua, Wang Zhan, Yang Haiyan, Tao Wei, Zheng Hongbo, Xu Qinqin, Yang Nong, Zeng Liang, Zhang Yongchang

Abstract excerpt

Brain metastases in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) frequently contribute to treatment failure. This phase II study aims to evaluate furmonertinib (160 mg daily) in 40 untreated patients with EGFR-mutant NSCLC and central nervous system (CNS) metastases. At a median follow-up of 18.66 months, the blinded independent central-review-assessed median progression-free...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Carcinoma, Non-Small-Cell Lung

Share to Central Nervous System Neoplasms

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 42379171
DOI: 10.1016/j.xcrm.2026.102904
PMCID: PMC13400170

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.PMID 42379171Read ↗

High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study.Semantic proximity Read ↗

Furmonertinib in uncommon EGFR-mutated non-small cell lung cancer with central nervous system metastases: A retrospective cohort study.Semantic proximity Read ↗

Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies.Semantic proximity Read ↗

Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM).Semantic proximity Read ↗

Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study.Semantic proximity Read ↗

Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study.Semantic proximity Read ↗

Furmonertinib combined with bevacizumab in EGFR-TKI-resistant leptomeningeal metastasis: analysis of the CSF ctDNA molecular response and survival outcomes.Semantic proximity Read ↗

Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS).Semantic proximity Read ↗

[Efficacy and Safety of High-dose Furmonertinib plus Intrathecal Pemetrexed for EGFR-mutant Non-small Cell Lung Cancer with Leptomeningeal Metastasis].Semantic proximity Read ↗

Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.Semantic proximity Read ↗

Significant benefit of high-dose furmonertinib in the treatment of leptomeningeal metastases from non-small-cell lung cancer with EGFR ex19Del mutation: Two case reports and a literature reviewSemantic proximity Read ↗

Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.